Here we report a study of PBGS activity in erythrocytes of subjects in whom there was no evidence of hematological disorders and in individuals with two types of hemoglobinopathy. Using the ratio method, we estimate a lower threshold for the blood Pb concentration that will inhibit erythrocyte PBGS activity than was previously reported for this method (18). We also find that use of the ratio method permits estimation of Pb exposure in children with sickle cell disease.
are considered to be the cells most sensitive to this biochemical effect of Pb (15) .
Of the many approaches for examining the relationship between Pb exposure and the inhibition of PBGS activity in erythrocytes, the European standardized PBGS assay has been widely used in epidemiological studies (16, 17) . Granick et al. (18) modified the basic assay procedure to include measurements of PBGS activity in erythrocytes in the presence or absence of D'VF, 20 rnmol/L, the activity determined in the presence of DTI' being termed "activated PBGS" activity. The ratio of activated to nonactivated PBGS activity is significantly correlated with the concentration of Pb in blood.
Here we report a study of PBGS activity in erythrocytes of subjects in whom there was no evidence of hematological disorders and in individuals with two types of hemoglobinopathy. Using the ratio method, we estimate a lower threshold for the blood Pb concentration that will inhibit erythrocyte PBGS activity than was previously reported for this method (18) . We also find that use of the ratio method permits estimation of Pb exposure in children with sickle cell disease.
Materials and Methods

Apparatus
We determined Pb in blood by anodic stripping voltanimetry, using a Model 3010A Rapid Blood Analyzer (Environmental Science Associates, Bedford, MA 01730). Deionized water, used for cleaning of glass-and plastic-ware and for preparing reagents, was prepared with a Model 4C2-44 "ultrapure" water system (Hydro Service and Supplies, Inc., Research Thangle Park, NC 27709).
Materials
(and their sources) were: NaH2PO4 . H20, Na2HPO4 . 7H20, trichloroacetic acid, and p-dimethylami- 
Reagents
Dissolve 2.68 g of Na2HPO4 -7H2O in 100 mL of deionized water (solution A) and dissolve 1.38 g of Nail2-P04 -H20 in 100 mL of de-ionized water (solution B). Mix 29 inL of solution A and 71 mL of solution B to prepare 0.1 mol/L phosphate buffer, pH 6.4 ± 0.02. To prepare the ALA solution, dissolve 167.6 mg of ALA -HC1 in 20 mL of solution B, adjust to pH 6.4 with solution A and dilute to 100 mL with the phosphate buffer.
To prepare DTF-containing ALA solution, dissolve 154.3 mg of DTF in 50 mL of ALA solution. To prepare Hg-TCA solution, dissolve 1.35 g of HgCl2 in 100 mL of 100 g/L trichloroacetic acid. To prepare modified Ehrlich's reagent, dissolve 0.25 g of HgCl2 in 10 mL of glacial acetic acid (Hg solution) and dissolve 2.5 g of p-dimethylaminobenzaldehyde in 50 mL of glacial acetic acid. To this solution add 24.5 mL of perchloric acid and 4 mL of the HgC12 solution. Mix well and dilute to 100 mL with glacial acetic acid. Allow to cool to room temperature before use, and store in a dark bottle.
Modified Ehrlich's reagent must be prepared daily. ALAand ifiT-containing ALA solutions can be stored at 4#{176}C for up to one week. Prepare the phosphate buffer in bulk; store at -20 #{176}C until used.
Precautions to Minimize Contamination with Lead and Zinc
Because PBGS activity is increased by exogenous Zn (7,9) and inhibited by exogenous Pb (3,4), we took care to avoid contamination of samples during collection and processing (19), washing all glass-and plastic-ware in Acationox detergent solution, soaking them overnight in 1 mol/L hydrochloric acid, then rinsing them seven times with de-ionized water and draining and drying on Whatman no. 40 fIlter paper.
To minimize the risk of metal contamination during blood collection, we used polyethylene-polypropylene syringes
and sodium heparin with low Zn content. PBGS assays were performed in acid-washed borosilicate tubes, which were discarded after a single use. To eliminate contamination with Zn from paper, we used Whatman no. 40 ifiter paper instead of regular paper towels (e.g., to wipe outside of pipet tips).
Procedures
Blood collection and processing. for PBGS analysis were immediately transferred to acidwashed 1.5-mL polyethylene tubes, which contained 3 jiL of sodium heparin as anticoagulant.
After thorough mixing, samples were frozen within 3 mm on solid carbon dioxide and stored at -70 #{176}C.
Blood Pb and FEP analyses. We determinod the Pb concentration in duplicate 0.10-mL aliquots of blood by anodic stripping voltanimetry (20) Thaw frozen blood and sonicate to ensure its complete liquification. Hemolyze the sample by transferring 0.2-mL aliquots with an SMI positive-displacement pipet (VWR Scientific) to acid-washed borosilicate tubes containing 1.3 mL of de-ionized water. Before each such transfer, remove any excess blood on the outside of the pipet tip by wiping it with Whatman no. 40 filter paper (9-cm discs), andrinse the pipet tip twice with the contents of the tube.
Incubate the mixture at 37 #{176}C for 10 mm to hemolyze erythrocytes.
Prepare five aliquots for each sample (two for activated assay, two for nonactivated assay, one for the blank). Filter the supernate through Whatman no. 541 paper and collect the ifitrate in polypropylene tubes.
Form the chromogen by adding 1 mL of modified Ehrlich's reagent to 1 mL of filtrate. Allow the samples to stand for 5 mm at room temperature after adding the modified Ehrlich's reagent. Determine the absorbance of the samples at 555 nm, using cuvettes with a 1-cia lightpath. Net absorbances of activated and nonactivated assays are the differences between absorbance of these assays and the blank.
Calculate activity, (pmol ALA utilized)/(min/L of erythrocytes), as Activity = (net absorbance x 100 x 2 x 35)I(% hematocrit x 60 x 0.062), where 2 is the conversion factor for ALA to porphobilinogen, 35 is the dilution factor, 60 is the incubation time (mm), and 0.062 is the micromolar absorptivity of modified Ehrlich's reagent-porphobilinogen chromogen.
Calculate the ratio of activated to nonactivated PBGS activity.
Results
Stability of PBGS activity during storage. Preliminary results indicated that storage of blood samples at -20 #{176}C results in a rapid decline in activated and nonactivated PBGS activities, confirming the report of Granick et al. (18) . As an alternative, blood samples for PBGS analysis were immediately and rapidly frozen on solid carbon dioxide (-78 #{176}C) at the time of collection and stored at -70 #{176}C until used. Storage for one to 43 days at -70#{176}C was associated with 13 to 24% increases in both nonactivated and activated PBGS activities (Table 1) . Because the activities of both nonactivated and activated PBGS increased upon freezing and remained stable dunng'storage, PBGS activity ratios for fresh and frozen samples were equivalent.
The mean difference for 57 duplicate determinations of the activated! monactivated PBGS ratio was 0.076. We performed all PBGS activity assays within 30 days of sample collection.
Relationship
between blood lead concentration and PBU activity. We determined nonactivated and activated PBGS activity in blood obtained from 57 children (27 black males, 20 black females, seven white males, and three white CWIthjn 2 h after collection.
females) who had no evidence of hemoglobinopathy. The median age of these children was 54 months (range nine to 183 months) and the concentration of Pb in blood ranged from 0.14 to 1.93 imol/L. Figure 1 (left) shows the significant negative correlation between the concentration of Pb in blood ad the nonactivated activity of erythrocyte PBGS in these children; Figure 1 (middle) shows that between the Pb concentration in blood and the DIT-activated PBGS activity in erythrocytes;
and Figure 1 (right) shows that between Pb concentration in blood and the activated/nonactivated PBGS activity ratio in erythrocytes.
In the last is also shown the 95% confidence interval about the regression lime. The Table 2 summarizes these data and compares observed values for the activated, nonactivated, and the ratios of PBGS activities with those predicted from the regression equations fitted to data obtained from normal children. For eight subjects with sickle cell disease the observed nonactivated and activated PBGS activities substantially exeeded the values predicted from their blood Pb concentrations.
By contrast, the ratios for activated/nonactivated PBGS activity for these individuals' erythrocytes were close to those predicted from data obtained for normal children. In subjects with /3-thalassemia, observed values for nonactivated and activated PBGS activities and for activity ratios were close to those predicted by data for normal children. The nonactivated and activated PBGS activities for eiythrocytes of siblings with FEP concentrations abovenormal for unknown reasons were much below those predicted from the Pb concentration in blood, but the observed and predicted ratios agreed closely.
Discussion
Two methodological factors contributed to the usefulness of the method reported here. First, rapid freezing of blood samples in solid carbon dioxide and storage at -70 #{176}C until analysis prevented loss of enzyme activity (Table 1) . Second, precautions minimizing the hazard of Zn and Pb contamination of samples and of glassware lessened the chance of enzyme activation or inhibition during collection and processing of samples. The results of the present study indicated that erythrocyte PBGS activity sensitively indicates Pb exposure, being highly correlated with the concentration of Pb in blood. In contrast, we did not find significant correlations between FEP and activated or nonactivated PBGS activities or between FEP and the ratio between activated and nonactivated PJ3GS activity.
Use of the activatedlnonactivated PBGS activity ratio as
an indicator of Pb exposure requires recognition of those factors that may affect both the activated and nonactivated activities of the enzyme. We found that both nonactivated and activated PBGS activities of erythrocytes from children without hemoglobinopathy varied over a wide range ( Figure  1) . These findings are consistent with earlier reports of wide variation in erythrocyte PBGS activity, reflecting the relatively high polymorphism for PBGS activities in humans (22, 23) .
Another feature of the relationship between the Pb concentration in blood and the activated PBGS activity is the significant negative correlation between the two variables. for the enzyme's activity as a function of increasing blood Pb concentration (10, 11,24). Although reported pH optima for activity of PBGS in erythrocytes of individuals with normal (i.e., low) Pb exposure ranges from pH 6.4 to 6.8, an increasing blood Pb concentration is accompanied by a shift in the pH optimum toward pH 6 or less. A noticeable shift in pH optimum has been observed when blood Pb concentrations are as low as 1.23 pmol/L.
We found the nonactivated PBGS activities in the eryth-1-ocytes of individuals with sickle cell disease to be uniformly above the predicted values (Table 2) . Because erythrocyte PBGS activities reportedly are increased in individuals with anemia (25, 26), the increased activity in subjects with sickle cell disease may reflect the younger age of the circulating erythrocytes in these subjects. If the nonactivated PBGS activity were to be used as a predictor of blood Pb concentration in individuals with sickle cell disease, then a spuriously low Pb concentration in blood would be predicted. However, use of the activated/nonactivated PBGS activity ratios for these individuals resulted in values that more closely approximated those predicted by their blood Pb concentration.
We did not find this discrepancy in predicted and observed nonactivated PBGS activity in subjects with /3-thalassemia.
In the two siblings with increased FEP concentrations in the absence of anemia and with very low blood Pb concentrations, both activated and nonactivated PBGS activities were extremely low. Although their parents were not available for study, we suggest that these siblings had an hereditary decrease in erythrocyte PBGS activity consistent with previous reports of individuals with genetically determined very low erythrocyte PBGS activities (27-29). Use of nonactivated PBGS activity alone as a predictor of their concentration of Pb in blood, as in the European standardized and other similar PBGS assay methods, would have resulted in a spuriously high estimate for Pb.
The biological significance of Pb-dependent inhibition of PBGS activity is not well understood.
Inherited deficiency of PBGS activity is not associated with anemia (27-29); this suggests that the remaining enzyme activity suffices to meet the demands of hemoglobin synthesis. However, because Pb inhibits PBGS in nonhematopoietic tissues, including the central nervous system (14), Pb in relatively low concentrations may also inhibit this enzyme in other tissues.
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